CHF Solutions raises funds for fluid overload device
This article was originally published in Clinica
A Brooklyn, Minnesota firm developing filtration technology to treat fluid overload in patients with congestive heart failure has raised $22.9m from venture capitalists. CHF Solutions says the funds will finance a clinical trial of its system in 200 patients, and the expansion of a marketing programme.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.